Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Ascendis Pharma A (ASND) Equity Average (2017 - 2025)

Ascendis Pharma A's Equity Average history spans 7 years, with the latest figure at $56.0 million for Q4 2023.

  • For Q4 2023, Equity Average fell 91.25% year-over-year to $56.0 million; the TTM value through Dec 2023 reached $56.0 million, down 91.25%, while the annual FY2023 figure was $60.0 million, 90.93% down from the prior year.
  • Equity Average for Q4 2023 was $56.0 million at Ascendis Pharma A, down from $639.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.0 billion in Q4 2021 and bottomed at $56.0 million in Q4 2023.
  • The 5-year median for Equity Average is $639.8 million (2022), against an average of $604.4 million.
  • The largest annual shift saw Equity Average soared 81.56% in 2019 before it tumbled 91.25% in 2023.
  • A 5-year view of Equity Average shows it stood at $490.3 million in 2019, then soared by 69.38% to $830.5 million in 2020, then grew by 21.07% to $1.0 billion in 2021, then tumbled by 36.37% to $639.8 million in 2022, then crashed by 91.25% to $56.0 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Equity Average are $56.0 million (Q4 2023), $639.8 million (Q4 2022), and $1.0 billion (Q4 2021).